SJBT031026_D2.RNA-Seq
EPN · Spinal EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Spinal EPN
- cancer_type
- EPN
- subtype
- Spinal EPN
- age_years
- 16.28
- e1_e2
- E1
- umap1_2d
- -1.49975486
- umap2_2d
- 2.646304678
- umap1_3d
- -0.047070777
- umap2_3d
- -0.262099345
- umap3_3d
- -1.016354983
- dataset
- EPN-StJude
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7724-01A-11R-2170-07 | — | cohortMD2 | 0.796 |
| 2 | C3N-04168 | — | cohortMD2 | 0.788 |
| 3 | 2aefe8ef-5ffd-4c0d-8550-2573eb6fb051 | — | — | 0.785 |
| 4 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.772 |
| 5 | SRR25617837 | — | C | 0.770 |
| 6 | SRR8518405 | — | A | 0.769 |
| 7 | SRR12475115 | — | — | 0.768 |
| 8 | TCGA-44-A479-01A-31R-A24H-07 | — | cohortA3 | 0.768 |
| 9 | SRR12475112 | — | — | 0.766 |
| 10 | TCGA-E9-A24A-01A-11R-A169-07 | — | B | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |